IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. (“Emergent” or the “Company”) (NYSE: EBS). Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline.
If you purchased shares of Emergent during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, Emergent issued materially false and misleading statements about its business and financial prospects, specifically relating to future lucrative contract renewals and demand from the U.S. government for its anthrax vaccine BioThrax. These statements caused the Company’s common stock to trade at artificially inflated prices, which certain defendants were able to sell. On June 22, 2016 Emergent announced that the U.S. government issued notices that it would be purchasing a smaller number of doses than investors were led to believe, and that when newer and faster next-generation anthrax vaccines are developed and approved, the Company would lose its procurement contract exclusivity. When this news was released, shares of the stock fell in value.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.